OCULAR THERAPEUTIX, INC Payments for Restructuring
OCULAR THERAPEUTIX, INC (OCUL) reported Payments for Restructuring of $1.21 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2024-11-14
- OCULAR THERAPEUTIX, INC payments for restructuring for the quarter ending 2024-09-30 was $1.21M.
- OCULAR THERAPEUTIX, INC payments for restructuring for the quarter ending 2024-06-30 was $395.00K.
- OCULAR THERAPEUTIX, INC payments for restructuring for the quarter ending 2018-12-31 was $138.00K, a 78.40% decline year-over-year.
- OCULAR THERAPEUTIX, INC payments for restructuring for the quarter ending 2018-09-30 was $230.00K, a 74.64% decline year-over-year.
- OCULAR THERAPEUTIX, INC payments for restructuring for fiscal 2018 was $960.00K, a 37.90% decline from fiscal 2017.
- OCULAR THERAPEUTIX, INC payments for restructuring for fiscal 2017 was $1.55M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-09-30 | $1.21M 10-Q · filed 2024-11-14 | $1.60M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2024-06-30 | $395.00K 10-Q · filed 2024-11-14 | |||
| 2018-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $368.00K derived: sum of 2 quarters · filed 2019-03-07 | $659.00K derived: sum of 3 quarters · filed 2019-03-07 | $960.00K 10-K · filed 2019-03-07 |
| 2018-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $521.00K derived: sum of 2 quarters · filed 2018-11-07 | $822.00K 10-Q · filed 2018-11-07 | $1.46M derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | $291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $592.00K 10-Q · filed 2018-08-07 | $1.23M derived: sum of 3 quarters · filed 2018-08-07 | $2.14M derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | $301.00K 10-Q · filed 2018-05-08 | $940.00K derived: sum of 2 quarters · filed 2018-05-08 | $1.85M derived: sum of 3 quarters · filed 2018-05-08 | |
| 2017-12-31 | $639.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.55M derived: sum of 2 quarters · filed 2018-03-08 | $1.55M 10-K · filed 2018-03-08 | |
| 2017-09-30 | $907.00K 10-Q · filed 2017-11-07 | $907.00K 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |